Skip to main content
SpringerLink
Log in
Book cover

Schizophrenia pp 107–138Cite as

Acute Management of Schizophrenia

  • Chapter
  • First Online:

  • 4448 Accesses

Abstract

The management of schizophrenia begins with the early recognition of high-risk individuals or those who are experiencing subtle psychotic symptoms prior to a first full episode. Timely and effective interventions at these phases may preclude or attenuate the impact of acute psychosis and favorably alter one’s prognosis. In first-episode/early-onset patients, strategies to optimize medication administration and improve adherence can also improve long-term outcomes. In multiepisode patients with acute exacerbations, insufficient benefit and/or safety and tolerability complications are frequent obstacles to achieving stabilization. Thus, the development of alternate strategies is critically important and being actively pursued. At all phases, the goal is to achieve adequate control of symptoms, allowing patients to move from response to remission to recovery.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Janicak PG, Marder S, Pavuluri M. Principles and practice of psychopharmacotherapy. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011. p. 65–180.

    Google Scholar 

  2. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–23.

    PubMed  CAS  Google Scholar 

  3. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry. 2006;63(10):1079–87.

    PubMed  CAS  Google Scholar 

  4. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71–93.

    PubMed Central  PubMed  Google Scholar 

  5. Wang L, McLeod HL, Weinshilbourn RM. Genomics and drug response. N Engl J Med. 2011;364(12):1144–53.

    PubMed Central  PubMed  CAS  Google Scholar 

  6. Malhotra AK. The state of pharmacogenetics: customizing treatments. Psychiatr Times. 2010;27(4):38–41.

    Google Scholar 

  7. Xu M, Xing Q, Li S, Zheng Y, Wu S, Gao R, et al. Pharmacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(6):1026–32.

    PubMed  CAS  Google Scholar 

  8. Kohlrausch FB, Salatino-Oliveira A, Gama CS, Lobato MI, Belmonte-de-Abreu P, Hutz MH. Influence of serotonin transporter gene polymorphisms on clozapine response in Brazilian schizophrenics. J Psychiatr Res. 2010;44(16):1158–62.

    PubMed  Google Scholar 

  9. Lencz T, Morgan TV, Athanasiou M, Dain B, Reed CR, Kane JM, et al. Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol Psychiatry. 2007;12:572–80.

    PubMed  CAS  Google Scholar 

  10. Lavedan C, Licamele L, Volpi S, Hamilton J, Heaton C, Mack K, et al. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol Psychiatry. 2009;14(8):804–19.

    PubMed  CAS  Google Scholar 

  11. Fijal BA, Stauffer VL, Kinon BJ, et al. Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone. J Clin Psychiatry. 2012;73(3):367–71.

    PubMed  CAS  Google Scholar 

  12. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166:152–63.

    PubMed  Google Scholar 

  13. Yilmaz Z, Zai CC, Hwang R, Mann S, Arenovich T, Remington G, et al. Antipsychotics, dopamine D2 receptor occupancy and clinical improvement in schizophrenia: a meta-analysis. Schizophr Res. 2012;140(1–3):214–20.

    PubMed  Google Scholar 

  14. Janicak PG, Javaid JI, Leach A, Sharma RP, Dowd S, Davis JM. A two phase double-blind randomized study of three haloperidol plasma levels for acute psychosis with reassignment of initial non-responders. Acta Psychiatr Scand. 1997;95:343–50.

    PubMed  CAS  Google Scholar 

  15. Remington G, Agid O, Foussias G, Ferguson L, McDonald K, Powell V. Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold? Psychopharmacology (Berl). 2013;225(3):505–18.

    CAS  Google Scholar 

  16. Lopez LV, Kane JM. Plasma levels of second-generation antipsychotics and clinical response in acute psychosis: a review of the literature. Schizophr Res. 2013;147(2–3):368–74.

    PubMed  Google Scholar 

  17. Sparshatt A, Taylor D, Patel MX, Kapur S. A systematic review of aripiprazole—dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry. 2010;71(11):1447–56.

    PubMed  CAS  Google Scholar 

  18. Nazirizadeh Y, Vogel F, Bader W, et al. Serum concentrations of paliperidone versus risperidone and clinical effects. Eur J Clin Pharmacol. 2010;66(8):797–803.

    PubMed  CAS  Google Scholar 

  19. Bishara D, Olofinjana O, Sparshatt A, Kapur S, Taylor D, Patel MX. Olanzapine: a systematic review and meta-regression of the relationships between dose, plasma concentration, receptor occupancy, and response. J Clin Psychopharmacol. 2013;33:329–55.

    PubMed  CAS  Google Scholar 

  20. Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry. 2008;65(1):25–7.

    Google Scholar 

  21. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry. 2002;59:921–8.

    PubMed  Google Scholar 

  22. Fusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rossler A, Schultze-Lutter F, et al. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry. 2013;70(1):107–20.

    PubMed  Google Scholar 

  23. Zammit S, Kounali D, Cannon M, et al. Psychotic experiences and psychotic disorders at age 18 in relation to psychotic experiences at age 12 in a longitudinal population-based cohort study. Am J Psychiatry. 2013;170:742–50.

    PubMed  Google Scholar 

  24. Yung AR, Stanford C, Cosgrave E, Killackey E, Phillips L, Nelson B, et al. Testing the ultra high risk (prodromal) criteria for the prediction of psychosis in a clinical sample of young people. Schizophr Res. 2006;84(1):57–66.

    PubMed  Google Scholar 

  25. Ruhrmann S, Schulte-Lutter F, Salokangas RK, Heinimaa M, Linszen D, Dingemans P, et al. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry. 2010;67(3):241–51.

    PubMed  Google Scholar 

  26. Seidman LJ, Giuliano AJ, Meyer EC, Addington J, Cadenhead KS, Cannon TD, et al. Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch Gen Psychiatry. 2010;67(6):578–88.

    PubMed Central  PubMed  Google Scholar 

  27. Egerton A, Chaddock CA, Winton-Brown TT, et al. Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort. Biol Psychiatry. 2013;74:106–12.

    PubMed  CAS  Google Scholar 

  28. Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Cannon T, Ventura J, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2003;29(4):703–15.

    PubMed  Google Scholar 

  29. Tandon R. Schizophrenia spectrum and other psychotic disorders: DSM-5 revisions and their clinical implications. Psychopharm Rev. 2013;48(5):33–40.

    Google Scholar 

  30. Preti A, Cella M. Randomized-controlled trials in people at ultra high risk of psychosis; a review of treatment effectiveness. Schizophr Res. 2010;123(1):30–6.

    PubMed  Google Scholar 

  31. McGorry PD, Nelson B, Amminger GP, Bechdolf A, Francey SM, Berger G, et al. Intervention in individuals at ultra-high risk for psychosis: a review and future directions. J Clin Psychiatry. 2009;70(9):1206–12.

    PubMed  Google Scholar 

  32. Amminger GP, Schafer MR, Papageorgiu K, Klier CM, Cotton SM, Harrigan SM, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010;67(2):146–54.

    PubMed  CAS  Google Scholar 

  33. Asevedo E, Cunha GR, Zugman A, Mansur RB, Brietzke E. N-acetyl cysteine as a potentially useful medication to prevent conversion to schizophrenia in at-risk individuals. Rev Neurosci. 2012;23(4):353–62.

    PubMed  CAS  Google Scholar 

  34. Dean O, Giorlando F, Berk M. N-acetyl cysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci. 2011;36(2):78–86.

    PubMed Central  PubMed  Google Scholar 

  35. Liu CC, Chien YL, Hsieh MH, Hwang TJ, Hwu HG, Liu CM. Aripiprazole for drug-naïve or antipsychotic-short-exposure subjects with ultra-high risk state and first-episode psychosis: an open-label study. J Clin Psychopharmacol. 2013;33:18–23.

    PubMed  CAS  Google Scholar 

  36. McGorry PD, Nelson B, Phillips LJ, et al. Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome. J Clin Psychiatry. 2013;74(4):349–56.

    PubMed  CAS  Google Scholar 

  37. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry. 2005;162:1785–804.

    PubMed  Google Scholar 

  38. Boonstra N, Klaassen R, Sytema S, Marshall M, De Haan L, Wunderink L, et al. Duration of untreated psychosis and negative symptoms—a systematic review and meta-analysis of individual patient data. Schizophr Res. 2012;142(1–3):12–9.

    PubMed  Google Scholar 

  39. Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry. 2005;62:975–83.

    PubMed  Google Scholar 

  40. Perkins DO. Review: longer duration of untreated psychosis is associated with worse outcome in people with first episode psychosis. Evid Based Ment Health. 2006;9(2):36.

    PubMed  Google Scholar 

  41. Cuesta MJ, Garcia de Jalon E, Campos MS, Ibanez B, Sanchez-Torres AM, Peralata V. Duration of untreated negative and positive symptoms of psychosis and cognitive impairment in first episode psychosis. Schizophr Res. 2012;141(2–3):222–7.

    PubMed  Google Scholar 

  42. Andreasen NC, Nopoulos P, Magnotta V, Pierson R, Ziebell S, Ho BC. Progressive brain change in schizophrenia: a prospective longitudinal study of first-episode schizophrenia. Biol Psychiatry. 2011;70:672–9.

    PubMed Central  PubMed  Google Scholar 

  43. Lewis DA. Antipsychotic medications and brain volume: do we have cause for concern? Arch Gen Psychiatry. 2011;68(2):126–7.

    PubMed  Google Scholar 

  44. Ho B-C, Andreason NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry. 2011;68(2):128–37.

    PubMed Central  PubMed  Google Scholar 

  45. Bertelsen M, Jeppesen P, Peterson L, Thorup A, Øhlenschlaeger J, le Quach P, et al. Five-year follow-up of a randomized multicenter trial of intensive early intervention vs standard treatment for patients with a first episode of psychotic illness: the OPUS trial. Arch Gen Psychiatry. 2008;65(7):762–71.

    PubMed  Google Scholar 

  46. Melle I, Larsen TK, Haahr U, Friis S, Johannessen JO, Ojordsmoen S, et al. Reducing the duration of untreated first-episode psychosis: effects on clinical presentation. Arch Gen Psychiatry. 2004;61:143–50.

    PubMed  Google Scholar 

  47. Melle I, Johannesen JO, Friis S, Haahr U, Joa I, Larsen TK, et al. Early detection of the first episode of schizophrenia and suicidal behavior. Am J Psychiatry. 2006;163:800–4.

    PubMed  Google Scholar 

  48. ten Velden Hegelstad W, Larsen TK, Auestad B, Evensen J, Haahr U, Joa I, et al. Long-term follow-up of the TIPS early detection in psychosis study: effects on 10-year outcome. Am J Psychiatry. 2012;169:374–80.

    Google Scholar 

  49. Wunderink L, Nierboer RM, Wiersma D, Systema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry. 2013;70(9):913–20.

    PubMed  Google Scholar 

  50. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 2003;160:1396–404.

    PubMed  Google Scholar 

  51. Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L, et al. Atypical and conventional antipsychotic drugs in treatment-naïve first-episode schizophrenia: a 52-week randomized trial of clozapine vs. chlorpromazine. Neuropsychopharmacology. 2003;28:995–1003.

    PubMed  CAS  Google Scholar 

  52. Girgis RR, Philips MR, Xiaodong L, Kejin L, Jiang H, Wu C, et al. Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. Br J Psychiatry. 2011;199:281–8.

    PubMed  Google Scholar 

  53. Kumra S, Kranzler H, Gerbino-Rosen G, Kester HM, DeThomas C, Kafantaris V, et al. Clozapine and “high-dose” olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry. 2008;63:524–9.

    PubMed  Google Scholar 

  54. Harvey PD, Rabinowitz J, Eerdekens M, Davidson M. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry. 2005;162:1888–95.

    PubMed  Google Scholar 

  55. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry. 2005;162:947–53.

    PubMed  Google Scholar 

  56. Crespo-Facorro B, Rodriguez-Sanchez J, Perez-Iglesias R, Mata I, Ayesa R, Ramirez-Bonilla M, et al. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled one-year follow-up comparison. J Clin Psychiatry. 2009;70(5):717–29.

    PubMed  CAS  Google Scholar 

  57. McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164:1050–60.

    PubMed  Google Scholar 

  58. Keefe RSE, Sweeney JA, Gu H, Gu H, Hamer RM, Perkins DO, et al. Effects on olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164:1061–71.

    PubMed  Google Scholar 

  59. Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: Findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry. 2008;165:1420–31.

    PubMed  Google Scholar 

  60. Kahn R, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in first episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085–97.

    PubMed  CAS  Google Scholar 

  61. Fleischhacker WW, Uchida H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int J Neuropsychopharmacol. 2012;2:1–11.

    Google Scholar 

  62. Crossley NA, Constante M, McGuire P, Power P. Efficacy of atypical v. typical antipsychotic in the treatment of early psychosis: meta-analysis. Br J Psychiatry. 2010;196:434–9.

    PubMed Central  PubMed  Google Scholar 

  63. Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA, et al. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry. 2008;69(1):106–13.

    PubMed  CAS  Google Scholar 

  64. Emsley R, Rabinowitz J, Medori R, Early Psychosis Global Working Group. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr Res. 2007;89(1–3):129–39.

    PubMed  Google Scholar 

  65. Allen MH, Feifel D, Lesem MD, Zimbroff DL, Ross R, Munzar P, et al. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(10):1313–21.

    PubMed  CAS  Google Scholar 

  66. Lesem MD, Tran-Johnson TK, Riesenberg RA, et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry. 2011;198(1):51–8.

    PubMed  Google Scholar 

  67. Tiihonen J, Suokas JT, Suvisaari JM, Haukka J, Korhonen P. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry. 2012;69(5):476–83.

    PubMed  CAS  Google Scholar 

  68. Fakra E, Azorin JM. Clozapine for the treatment of schizophrenia. Expert Opin Pharmacother. 2012;13(13):1923–35.

    PubMed  CAS  Google Scholar 

  69. Liffick E, Breier A. Pharmacotherapy of first-episode schizophrenia. Psychopharm Rev. 2010;45(6):41–8.

    Google Scholar 

  70. Kirkpatrick B. Understanding the physiology of schizophrenia. J Clin Psychiatry. 2013;74(3):e05.

    PubMed  Google Scholar 

  71. Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry. 2012;17(12):1206–27.

    PubMed  CAS  Google Scholar 

  72. Lochmann van Bennekom MW, Gijsman HJ, Zitman FG. Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness. J Psychopharmacol. 2013;27(4):327–36.

    PubMed  Google Scholar 

  73. Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD006324.

    Google Scholar 

  74. Barbui C, Accordini S, Nose M, Stroup S, Purgato M, Girlanda F, et al. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial. J Clin Pharmacol. 2011;31(3):266–73.

    CAS  Google Scholar 

  75. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs. monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull. 2009;35(2):443–57.

    PubMed Central  PubMed  Google Scholar 

  76. Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl). 2004;174(1):3–16.

    CAS  Google Scholar 

  77. Snitz BE, MacDonald III A, Cohen JD, Cho RY, Becker T, Carter CS. Lateral and medial hypofrontality in first-episode schizophrenia: functional activity in a medication-naïve state and effects of short-term atypical antipsychotic treatment. Am J Psychiatry. 2005;162(12):2322–9.

    PubMed  Google Scholar 

  78. Mu Q, Johnson K, Morgan PS, Grenesko EL, Molnar CE, Anderson B, et al. A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia. Schizophr Res. 2007;94(1–3):333–41.

    Google Scholar 

  79. George MS, Molnar CE, Grenesko EL, et al. A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia. Schizophr Res. 2007;93(1–3):42–50.

    PubMed  Google Scholar 

  80. Siever LJ, Zaluda LC, McClure MM, et al. Clinical testing of a D1 agonist for cognitive enhancement in the schizophrenia spectrum. Presented at: 14th International Congress on Schizophrenia Research, April 21–25, 2013; Grand Lakes, FL.

    Google Scholar 

  81. Jardemark K, Marcus MM, Shahid M, Svensson TH. Effects of asenapine on prefrontal N-methyl-d-aspartate receptor-mediated transmission: involvement of dopamine D1 receptors. Synapse. 2010;64(11):870–4.

    PubMed  CAS  Google Scholar 

  82. Lai C, Mo GH, Chen ML, Wang YC, Chen JY, Liao DL. Analysis of genetic variations in the dopamine D1 receptor (DRD1) gene and antipsychotics-induced tardive dyskinesia in schizophrenia. Eur J Pharmacol. 2011;67(4):383–4.

    CAS  Google Scholar 

  83. Hwang R, Zai C, Tiwari A, Muller DJ, Arranz MJ, Morris AG, et al. Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. Pharmacogenomics J. 2010;10(3):200–18.

    PubMed  CAS  Google Scholar 

  84. Jardemark K, Wadenberg ML, Grillner P, Svensson TH. Dopamine D3 and D4 receptor antagonists in the treatment of schizophrenia. Curr Opin Investig Drugs. 2002;3(1):101–5.

    PubMed  CAS  Google Scholar 

  85. Grunder G. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression. Curr Opin Investig Drugs. 2010;11(7):823–32.

    PubMed  Google Scholar 

  86. Gross G, Drescher K. The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions. Handb Exp Pharmacol. 2012;213:167–210.

    PubMed  CAS  Google Scholar 

  87. Kelleher JP, Centorrino F, Huxley NA, et al. Pilot randomized, controlled trial of pramipexole to augment antipsychotic treatment. Eur Neuropsychopharmacol. 2012;22:415–8.

    PubMed  CAS  Google Scholar 

  88. Gross G, Wicke K, Drescher KU. Dopamine D3 receptor antagonism—still a therapeutic option for the treatment of schizophrenia. Naunyn Schmiedebergs Arch Pharmacol. 2013;386(2):155–66.

    PubMed  CAS  Google Scholar 

  89. Yamamoto K, Hornykiewicz O. Proposal for a noradrenaline hypothesis of schizophrenia. Prog NeuroPsychopharmacol Biol Psychiatry. 2004;28:913–22.

    PubMed  CAS  Google Scholar 

  90. Masana M, Bortolozzi A, Artigas F. Selective enhancement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia. Int J Neuropsychopharmacol. 2011;14(1):53–68.

    PubMed  CAS  Google Scholar 

  91. Kelly DL, Buchanan RW, Boggs DL, McMahon RP, Dickenson D, Nelson M, et al. A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. J Clin Psychiatry. 2009;70(4):518–25.

    PubMed  CAS  Google Scholar 

  92. Poyurovsky M, Faragian S, Fuchs C, Pashinian A. Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: add-on, double-blind placebo-controlled study. Isr J Psychiatry Relat Sci. 2009;46(3):213–20.

    PubMed  Google Scholar 

  93. Marcus MM, Jardemark K, Malmerfelt A, Bjorkholm C, Svensson TH. Reboxetine enhances the olanzapine-induced antipsychotic-like effect, cortical dopamine outflow and NMDA receptor-mediated transmission. Neuropsychopharmacology. 2010;35(9):1952–61.

    PubMed Central  PubMed  CAS  Google Scholar 

  94. Bjorkholm C, Jardemark K, Marcus MM, Malmerfelt A, Nyberg S, Schilstrom B, et al. Role of concomitant inhibition of the norepinephrine transporter for the antipsychotic effect of quetiapine. Eur Neuropsychopharmacol. 2013;23(7):709–20.

    PubMed  Google Scholar 

  95. Meltzer HY, Massey BW, Horiguchi M. Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia. Curr Pharm Biotechnol. 2012;13(8):1572–86.

    PubMed  CAS  Google Scholar 

  96. Lerond J, Lothe A, Ryviln P, et al. Effects of aripiprazole, risperidone, and olanzapine on 5-HT1A receptors in patients with schizophrenia. J Clin Psychopharmacol. 2013;33:84–9.

    PubMed  CAS  Google Scholar 

  97. Bennett AC, Vila TM. The role of ondansetron in the treatment of schizophrenia. Ann Pharmacother. 2010;44(7–8):1301–6.

    PubMed  CAS  Google Scholar 

  98. Meltzer HY, Elkis H, Vanover K, Weiner DM, van Kammen DP, Peters P, et al. Primavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2 mg/day, but does not enhance efficacy of haloperidol, 2 mg/day: comparison with reference dose risperidone, 6 mg/day. Schizophr Res. 2012;141(2–3):144–52.

    PubMed  Google Scholar 

  99. Rosenzweig-Lipson S, Comery TA, Marquis KL, Gross J, Dunlop J. 5-HT(2C) agonists as therapeutics for the treatment of schizophrenia. Handb Exp Pharmacol. 2012;213:147–65.

    PubMed  CAS  Google Scholar 

  100. Morozova MA, Beniashvili AG, Lepilkina TA, Rupchev GE. Double-blind placebo-controlled randomized efficacy and safety trial of add-on treatment of dimebon plus risperidone in schizophrenic patients during transition from acute psychotic episode to remission. Psychiatr Danub. 2012;24(2):159–66.

    PubMed  Google Scholar 

  101. Kongsamut S, Roehr JE, Cai J, Hartman HB, Weissensee P, Kerman LL, et al. Iloperidone bingind to human and rat dopamine and 5-HT receptors. Eur J Pharmacol. 1996;317(2–3):417–23.

    PubMed  CAS  Google Scholar 

  102. Shadid M, Walker GB, Zorn SH, Wong EH. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009;23(1):65–73.

    Google Scholar 

  103. McIntyre RS, Cha DS, Alsuwaidan M, McIntosh D, Powell AM, Jerrell JM. A review of published evidence reporting on the efficacy and pharmacology of lurasidone. Expert Opin Pharmacother. 2012;13(11):1653–9.

    PubMed  CAS  Google Scholar 

  104. Konradi C, Heckers S. Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol Ther. 2003;97(2):153–79.

    PubMed  CAS  Google Scholar 

  105. Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology. 2012;37(1):4–15.

    PubMed Central  PubMed  CAS  Google Scholar 

  106. Hallak JE, Maia-de-Oliveria JP, Abrao J, et al. Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial. JAMA Psychiatry. 2013;70(7):668–76.

    PubMed  CAS  Google Scholar 

  107. Singh SP, Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs. 2011;25(10):859–85.

    PubMed  CAS  Google Scholar 

  108. Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, et al. The cognitive and negative symptoms in schizophrenia trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry. 2007;164(10):1593–602.

    PubMed  Google Scholar 

  109. Weiser M, Heresco-Levy U, Davidson M, Javitt DC, Werbeloff N, Gershon AA, et al. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. J Clin Psychiatry. 2012;73(6):e728–34.

    PubMed  CAS  Google Scholar 

  110. Chue P. Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1). Curr Pharm Des. 2013;19(7):1311–20.

    PubMed  CAS  Google Scholar 

  111. Lane HY, Lin CH, Huang YJ, Liao CH, Chang YC, Tsai GE, et al. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methyl glycine) and d-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol. 2010;13(4):451–60.

    PubMed  CAS  Google Scholar 

  112. Lane HY, Liu YC, Huang CL, Chang YC, Liau CH, Perng CH, et al. Sarcosine (N-methyl glycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry. 2008;63(1):9–12.

    PubMed  CAS  Google Scholar 

  113. Roche Global Web Site [Homepage on the Internet]. Phase II study with first-in-class investigational drug demonstrates improvement in negative symptoms in patients with schizophrenia. [Basel, December 6, 201]. http://www.roche.com/investors/ir_update/inv-update-2010-12-06b.htm.

  114. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, et al. Activation of nGlu2/3 receptors as new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med. 2007;13(9):1102–7.

    PubMed  CAS  Google Scholar 

  115. Kinon BJ, Zhang L, Millen BA, Osuntokun OO, Williams JE, Kollack-Walker S, et al. A ulticenter, inpatient, phase 2, double-blind, placebo-controlled, dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol. 2011;31(3):349–55.

    Google Scholar 

  116. Kinon BJ, Gomez JC. Clinical development of pomaglumetad methionil: a non-dopaminergic treatment for schizophrenia. Neuropharmacology. 2013;66:82–6.

    PubMed  CAS  Google Scholar 

  117. Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia—a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008;64:361–8.

    PubMed  CAS  Google Scholar 

  118. Farokhnia M, Azarkolah A, Adinehfar F, Khodaie-Ardakani MR, Hosseini SM, Yekehtaz H, et al. N-acetyl cysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2013;36(6):185–92.

    PubMed  CAS  Google Scholar 

  119. Goff DC, Leahy L, Berman I, Posever T, Herz L, Leon AC, et al. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol. 2001;21(5):484–7.

    PubMed  CAS  Google Scholar 

  120. Tiihonen J, Wahlbeck K, Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2009;109(1–3):10–4.

    PubMed  Google Scholar 

  121. deLucena D, Fernandes BS, Berk M, Dodd S, Medeiros DW, Pedrini M, et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry. 2009;70(10):1416–23.

    CAS  Google Scholar 

  122. Wassef A, Baker J, Kochan LD. GABA and schizophrenia: a review of basic science and clinical studies. J Clin Psychopharmacol. 2003;23(6):601–40.

    PubMed  CAS  Google Scholar 

  123. Geffen Y, Keefe R, Rabinowitz J, Anand R, Davidson M. Bl-1020, a new y-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study. J Clin Psychiatry. 2012;73(9):e1168–74.

    PubMed  CAS  Google Scholar 

  124. Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak P, Sommerville KW. Effect of divaloproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology. 2003;28(1):182–92.

    PubMed  CAS  Google Scholar 

  125. Casey DE, Daniel DG, Tamminga C, Kane JM, Tran-Johnson T, Wozniak P, et al. Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia. Neuropsychopharmacology. 2009;34(5):1330–8.

    PubMed  CAS  Google Scholar 

  126. Glick ID, Bosch J, Casey DE. A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive. J Clin Psychopharmacol. 2009;29(3):267–71.

    PubMed  CAS  Google Scholar 

  127. Lewis DA, Cho RY, Carter CS, Eklund K, Forster S, Kelly MA, et al. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am J Psychiatry. 2008;165:1585–93.

    PubMed Central  PubMed  Google Scholar 

  128. Hasan A, Wobrock T, Grefkes C, Labusga M, Levold K, Schneider-Axmann T, et al. Deficient inhibitory cortical networks in antipsychotic-naïve subjects at risk of developing first-episode psychosis and first-episode schizophrenia patients: a cross sectional study. Biol Psychiatry. 2012;72:744–51.

    PubMed  Google Scholar 

  129. Kegeles LS, Mao X, Stanford AD, Girgis R, Ojeil N, Xu X, et al. Elevated prefrontal cortex γ-aminobutric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 2012;69(5):449–59.

    PubMed  CAS  Google Scholar 

  130. Buchanan RW, Keefe RS, Lieberman JA, Barch DM, Csernansky JG, Goff DC, et al. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry. 2011;69(5):442–9.

    PubMed Central  PubMed  CAS  Google Scholar 

  131. Ross RG, Hunter SK, McCarthy L, Beuler J, Hutchinson AK, Wagner BD, et al. Perinatal choline effects on neonatal pathophysiology related to later schizophrenia risk. Am J Psychiatry. 2013;170(3):290–8.

    PubMed Central  PubMed  Google Scholar 

  132. Ribeiz SR, Bassitt DP, Arrais JA, Avila R, Steffens DC, Bottino CM. Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature. CNS Drugs. 2010;24(4):303–17.

    PubMed  CAS  Google Scholar 

  133. Dempster EL, Toulopoulou T, McDonald C, Bramon E, Walshe M, Wickham H, et al. Episodic memory performance predicted by the 2b deletion in exon 6 of the “alpha 7-like” nicotinic receptor subunit gene. Am J Psychiatry. 2006;163(10):1832–4.

    PubMed  Google Scholar 

  134. Ishikawa M, Hashimoto K. α7 nicotinic acetylcholine receptor as a potential therapeutic target for schizophrenia. Curr Pharm Des. 2011;17(2):121–9.

    PubMed  CAS  Google Scholar 

  135. Wallace TL, Bertrand D. Alpha7 neuronal nicotinic receptors as a drug target in schizophrenia. Expert Opin Ther Targets. 2013;17(2):139–55.

    PubMed  CAS  Google Scholar 

  136. Zhang XY, Liu L, Liu S, Hong X, Chen DC, Xiu MH, et al. Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia. Am J Psychiatry. 2012;169:974–81.

    PubMed  Google Scholar 

  137. Tregellas JR, Tanabe J, Rojas DC, Shatti S, Olincy A, Johnson L, et al. Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia. Biol Psychiatry. 2011;69(1):7–11.

    PubMed Central  PubMed  CAS  Google Scholar 

  138. Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry. 2008;165(8):1040–7.

    PubMed Central  PubMed  Google Scholar 

  139. Freedman R, Olincy A, Harris JG, et al. An alpha7-nicotinic receptor agonist in combination with risperidone versus olanzapine. Presented at: 14th International Congress on Schizophrenia Research; April 21–25, 2013; Grand Lakes, FL.

    Google Scholar 

  140. Lieberman JA, Dunbar G, Segreti AC, Girgis SF, Beaver JS, et al. A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology. 2013;38(6):968–75.

    PubMed  CAS  Google Scholar 

  141. Shim JC, Jung DU, Jung SS, Seo YS, Cho DM, Lee JH, et al. Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial. Neuropsychopharmacology. 2012;37:660–8.

    PubMed Central  PubMed  CAS  Google Scholar 

  142. Meszaros ZS, Abdul-Malak Y, Dimmock JA, Wang D, Ajagbe TO, Batki SL. Varenicline treatment of concurrent alcohol and nicotine dependence in schizophrenia: a randomized, placebo-controlled pilot trial. J Clin Psychopharmacol. 2013;33:243–7.

    PubMed  CAS  Google Scholar 

  143. Ahmed AIA, Ali ANA, Kramers C, Harmark LVD, Burger DM, Verhoeven WMA. Neuropsychiatric adverse events of varenicline: a systematic review of published reports. J Clin Psychopharmacol. 2013;33:55–62.

    PubMed  CAS  Google Scholar 

  144. Conley RR, Boggs DL, Kelly DL, et al. The effects of galantamine on psychopathology in chronic stable schizophrenia. Clin Neuropharmacol. 2009;32(2):69–74.

    PubMed  CAS  Google Scholar 

  145. Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dubé S, Mallinckrodt C, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry. 2008;165(8):1033–9.

    PubMed  Google Scholar 

  146. Bridges TM, LeBois EP, Hopkins CR, Wood MR, Jones CK, Conn PJ, et al. The antipsychotic potential of muscarinic allosteric modulation. Drug News Perspect. 2010;23(4):229–40.

    PubMed  CAS  Google Scholar 

  147. Bolbecker AR, Shekhar A. Muscarinic agonists and antagonists in schizophrenia: recent therapeutic advances and future directions. Handb Exp Pharmacol. 2012;208:167–90.

    PubMed  CAS  Google Scholar 

  148. Dean B. Selective activation of muscarinic acetylcholine receptors for the treatment of schizophrenia. Curr Pharm Biotechnol. 2012;13(8):1563–71.

    PubMed  CAS  Google Scholar 

  149. Lebois EP, Jones CK, Lindsley CW. The evolution of histamine H3 antagonists/inverse agonists. Curr Top Med Chem. 2011;11(6):648–60.

    PubMed  CAS  Google Scholar 

  150. Schwartz JC. The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol. 2011;163(4):713–21.

    PubMed Central  PubMed  CAS  Google Scholar 

  151. Ito C. Histamine H3-receptor inverse agonists as novel antipsychotics. Cent Nerv Syst Agents Med Chem. 2009;9(2):132–6.

    PubMed  CAS  Google Scholar 

  152. Wei Z, Wang L, Zhang M, Xuan J, Wang Y, Liu Y, et al. A pharmacogenetic study of risperidone on histamine H3 receptor gene (HRH3) in Chinese Han schizophrenia patients. J Psychopharmacol. 2012;26(6):813–8.

    PubMed  Google Scholar 

  153. Meskanen K, Ekelund H, Laitinen J, et al. A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia. J Clin Psychopharmacol. 2013;33:472–8.

    PubMed  CAS  Google Scholar 

  154. Chaudhry IB, Husain N, Khan S, Badshah S, Deakin B, Kapur S. Amoxapine as an antipsychotic. J Clin Psychopharmacol. 2007;27:575–81.

    PubMed  CAS  Google Scholar 

  155. Sepehry AA, Potvin S, Elie R, Stip E, et al. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. J Clin Psychiatry. 2007;68(4):604–10.

    PubMed  CAS  Google Scholar 

  156. Singh SF, Singh V, Kar N, Chan K. Efficacy of antidepressant in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry. 2010;197(3):174–9.

    PubMed  Google Scholar 

  157. Zisook S, Kasckow JW, Golshan S, Fellows I, Solorzano E, Lehman D, et al. Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial. J Clin Psychiatry. 2009;70(4):562–71.

    PubMed  CAS  Google Scholar 

  158. Bodkin JA, Siris SG, Bermanzohn PC, Hennen J, Cole JO. Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia. Am J Psychiatry. 2005;162:388–90.

    PubMed  Google Scholar 

  159. Mico U, Bruno A, Pandolfo G, Romeo VM, Mallamace D, D’Arrigo C, et al. Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial. Int Clin Psychopharmacol. 2011;26(6):303–10.

    PubMed  Google Scholar 

  160. Phan SV, Kreys TJ. Adjunct mirtazapine for negative symptoms of schizophrenia. Pharmacotherapy. 2011;31(10):1017–30.

    PubMed  CAS  Google Scholar 

  161. Cho SJ, Yook K, Kim B, Choi TK, Lee S, Kim YW, et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(1):208–11.

    PubMed  CAS  Google Scholar 

  162. Terevnikov V, Stenberg JH, Tiihonen J, Joffe M, Burkin M, Tchoukhine E, et al. Add-on mirtazapine improves depressive symptoms in schizophrenia: a double-blind randomized placebo-controlled study with an open-label extension phase. Hum Psychopharmacol. 2011;26(3):188–93.

    PubMed  CAS  Google Scholar 

  163. Stenberg JH, Terevnikoz V, Joffe M, Tiihonen J, Tchouhine E, Burkin M, et al. More evidence on proneurocognitive effects of add-on mirtazapine in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(4):1080–6.

    PubMed  CAS  Google Scholar 

  164. Caforio G, Di Giorgio A, Rampino A, Rizzo M, Romano R, Raurisano R, et al. Mirtazapine add-on improves olanzapine effect on negative symptoms of schizophrenia. J Clin Psychopharmacol. 2013;33(6):810–2.

    PubMed  Google Scholar 

  165. Gallagher P, Watson S, Smith MS, Ferrier IN, Young AH. Effect of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia. Biol Psychiatry. 2005;57(2):155–61.

    Google Scholar 

  166. Ritsner MS. The clinical and therapeutic potentials of dehydroepiandrosterone and pregnenolone in schizophrenia. Neuroscience. 2011;191:91–100.

    PubMed  CAS  Google Scholar 

  167. Marx CE, Bradford DW, Hamer RM, Naylor JC, Allen TB, Lieberman JA, et al. Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence. Neuroscience. 2011;191:78–90.

    PubMed  CAS  Google Scholar 

  168. Ritsner MS, Gibel A, Shleifer T, Boguslavsky I, Zayed A, Maayan R, et al. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial. J Clin Psychiatry. 2010;71(10):1351–62.

    PubMed  CAS  Google Scholar 

  169. Fineberg AM, Ellman LM. Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia. Biol Psychiatry. 2013;73:951–66.

    PubMed  CAS  Google Scholar 

  170. Miller BJ, Gassama B, Sebastian D, Buckley P, Mellor A. Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2013;73:993–9.

    PubMed  CAS  Google Scholar 

  171. Muller N, Riedel M, Scheppach C, Brandstatter B, Sokullu S, Krampe K, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry. 2002;159:1029–34.

    PubMed  Google Scholar 

  172. Laan W, Grobbee DE, Selten JP, Heijnen CJ, Kahn RS, Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized. Double-blind, placebo-controlled trial. J Clin Psychiatry. 2010;71(5):520–7.

    PubMed  CAS  Google Scholar 

  173. Sommer IE, de Witt L, Begemann M, Kahn RS, et al. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice of a good start? A meta-analysis. J Clin Psychiatry. 2012;73(4):414–9.

    PubMed  CAS  Google Scholar 

  174. Levkovitz Y, Mendolovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010;71(2):138–49.

    PubMed  CAS  Google Scholar 

  175. Chaudhry IB, Hallak J, Husain N, Minhas F, Stirling J, Richardson P, et al. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol. 2013;26(9):1185–93.

    Google Scholar 

  176. Skosnik PD, Ranganathan M, D’Souza DC. Cannabinoids, working memory, and schizophrenia. Biol Psychiatry. 2012;71:662–3.

    PubMed  Google Scholar 

  177. Evins AE, Green AI, Kane JM, Murray RM. Does using marijuana increase the risk for developing schizophrenia? J Clin Psychiatry. 2013;74(4):e08.

    PubMed  Google Scholar 

  178. Skosnik PD, D’Souza DC, Steinmetz AB, Edwards CR, Vollmer JM, Hetrick WP, et al. The effect of cannabinoids on broadband EEG neural oscillations in humans. Neuropsychopharmacology. 2012;37(10):2184–93.

    PubMed Central  PubMed  CAS  Google Scholar 

  179. Kulkarni J, de Castella A, Fitzgerald B, Gurvich CT, Bailey M, Batholomeusz C, et al. Estrogen in severe mental illness: a potential new treatment approach. Arch Gen Psychiatry. 2008;65(8):955–60.

    PubMed  Google Scholar 

  180. Usall J, Heurta-Ramos E, Iniesta R, Cobo J, Araya S, Roca M, et al. Raloxifene as an adjunctive treatment for post menopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2011;72(11):1552–7.

    PubMed  CAS  Google Scholar 

  181. Begemann MJ, Dekker CF, van Lunenburg M, Sommer IE. Estrogen augmentation in schizophrenia: a quantative review of current evidence. Schizophr Res. 2012;141(2–3):179–84.

    PubMed  Google Scholar 

  182. Ghafari E, Fararouie M, Shirazi HG, Farhangfar A, Ghaderi F, Mohammadi A. Combination of estrogen and antipsychotics in the treatment of women with chronic schizophrenia. Clinical Schizophr Relat Psychoses. 2013;6(4):172–6.

    Google Scholar 

  183. MacDonald K, Feifel D. Oxytocin in schizophrenia: a review of evidence for its therapeutic effects. Acta Neuropsychiatr. 2012;24:130–46.

    PubMed Central  PubMed  Google Scholar 

  184. Weisman O, Feldman R. Oxytocin effects on the human brain: findings, questions, and future directions. Biol Psychiatry. 2013;74:158–9.

    PubMed  CAS  Google Scholar 

  185. Modabbernia A, Rezaei F, Salehi B, Jafarinia M, Ashrafi M, Tabrizi M, et al. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia: an 8-week, randomized, double-blind, placebo-controlled study. CNS Drugs. 2013;27(1):57–65.

    PubMed  CAS  Google Scholar 

  186. Lee MR, Wehring HJ, McMahon RP, et al. Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double-blind placebo controlled pilot study. Schizophr Res. 2013;145(1–3):110–5.

    PubMed  Google Scholar 

  187. Woolley J, Chuang B, Lam O, et al. The effects of oxytocin on social cognition and olfaction in patients with schizophrenia and healthy controls. Presented at: 14th International Congress on Schizophrenia Research; April 21–25, 2013; Grand Lakes, FL.

    Google Scholar 

  188. Marder SR. Oxytocin and social cognition training in schizophrenia. Presented at: 4th International Congress on Schizophrenia Research; April 21–25, 2013; Grand Lakes, FL.

    Google Scholar 

  189. Davis MD, Lee J, Horan WP, et al. A pilot study on the effects of single dose intranasal oxytocin on social cognition in schizophrenia. Presented at: 14th International Congress on Schizophrenia Research; April 21–25, 2013; Grand lakes, FL.

    Google Scholar 

  190. Fusar-Poli P, Berger G. Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies. J Clin Psychopharmacol. 2012;32:179–85.

    PubMed  CAS  Google Scholar 

  191. Gunawardana L, Smith GD, Zammit S, Whitley E, Gunnell D, Lewis S, et al. Pre-conception inter-pregnancy interval and risk of schizophrenia. Br J Psychiatry. 2011;199(4):338–9.

    PubMed  Google Scholar 

  192. Roffman JL, Lamberti JS, Achtyes E, Macklin EA, Galendez GC, Raeke LH, et al. Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. JAMA Psychiatry. 2013;6:1–9.

    Google Scholar 

  193. Burghardt KJ, Ellingrod VL. Detection of metabolic syndrome in schizophrenia and implications for antipsychotic therapy: is there a role for folate? Mol Diagn Ther. 2013;17(1):21–30.

    PubMed  CAS  Google Scholar 

  194. McGrath J, Brown A, St Clair D. Prevention and schizophrenia—the role of dietary factors. Schizophr Bull. 2011;37(2):272–83.

    PubMed Central  PubMed  Google Scholar 

  195. Eyles DW, Burne TH, McGrath JJ. Vitamin D, effects on brain development, adult brain functions and the links between low levels of vitamin D and neuropsychiatric diseases. Front Neuroendocrinol. 2013;34(1):47–64.

    PubMed  CAS  Google Scholar 

  196. McGrath JJ, Burne TH, Feron F, Mackay-Sim A, Eyles DW. Developmental vitamin D deficiency and risk of schizophrenia: a 10-year update. Schizophr Bull. 2010;36(6):1073–8.

    PubMed Central  PubMed  Google Scholar 

  197. McGrath JJ, Eyles DW, Pedersen CB, Anderson C, Ko P, Burne TH, et al. Neonatal vitamin D status and risk of schizophrenia: a population-based case–control study. Arch Gen Psychiatry. 2010;67(9):889–94.

    PubMed  CAS  Google Scholar 

  198. McGrath JJ, Saari K, Hakko H, Jokelainen J, Jones P, Jarvelin MR, et al. Vitamin D supplementation during the first year of life and risk of schizophrenia: a Finnish birth cohort study. Schizophr Res. 2004;67(2–3):237–45.

    PubMed  Google Scholar 

  199. Shean GD. Empirically based psychosocial therapies for schizophrenia: the disconnection between science and practice. Schizophr Res Treatment. 2013;2013:792769.

    PubMed Central  PubMed  Google Scholar 

  200. Lewis S, Tarrier N, Haddock G, Bentail R, Kinderman P, Kingdon D, et al. Randomised controlled trial of cognitive-behavioural therapy in early schizophrenia: acute-phase outcomes. Br J Psychiatry. 2002;43(Suppl):s91–7.

    CAS  Google Scholar 

  201. Tarrier N, Lewis S, Haddock G, Bentall R, Drake R, Kinderman P, et al. Cognitive-behavioural therapy in first-episode and early schizophrenia: 18-month follow-up of a randomised controlled trial. Br J Psychiatry. 2004;184:231–9.

    PubMed  Google Scholar 

  202. Startup M, Jackson MC, Bendix S. North Wales randomized controlled trial of cognitive behavior therapy for acute schizophrenia spectrum disorders: outcomes at 6 and 12 months. Psychol Med. 2004;34(3):413–22.

    PubMed  CAS  Google Scholar 

  203. Startup M, Jackson MC, Evans KE, Bendix S. North Wales randomized controlled trial of cognitive behavior therapy for acute schizophrenia spectrum disorders: two-year follow-up and economic evaluation. Psychol Med. 2005;35(9):1307–16.

    PubMed  Google Scholar 

  204. Bechdolf A, Knost B, Nelson B, Schneider N, Veith V, Yung AR, et al. Randomized comparison of group cognitive behavior therapy and group psychoeducation in acute patients with schizophrenia: effects on subjective quality of life. Aust N Z J Psychiatry. 2010;44(2):144–50.

    PubMed  Google Scholar 

  205. Schulz M, Gray R, Spiekermann AC, Behrens J, Driessen M. Adherence therapy following an acute episode of schizophrenia: a multi-centre randomised controlled trial. Schizophr Res. 2013;146(1–3):59–63.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Rush University Medical Center, 2150 West Harrison Street, Chicago, IL, 60612, USA

    Philip G. Janicak

Authors
  1. Philip G. Janicak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philip G. Janicak .

Editor information

Editors and Affiliations

  1. Department of Psychiatry, Rush University, Chicago, Illinois, USA

    Philip G. Janicak

  2. UCLA Semel Institute, Los Angeles, California, USA

    Stephen R. Marder

  3. College of Medicine, University of Florida, Gainesville, Florida, USA

    Rajiv Tandon

  4. Department of Psychiatry and Behavioral Sciences, Northwestern University, Chicago, Illinois, USA

    Morris Goldman

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Janicak, P.G. (2014). Acute Management of Schizophrenia. In: Janicak, P., Marder, S., Tandon, R., Goldman, M. (eds) Schizophrenia. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0656-7_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-0656-7_7

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-0655-0

  • Online ISBN: 978-1-4939-0656-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation